Total Penectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Total penectomy is the complete surgical removal of the penis and is the definitive surgical treatment for locally advanced or proximally located penile cancer that cannot be adequately excised with a functional residual organ. It is one of the most radical oncological procedures in urological surgery, and its profound anatomical and psychological consequences necessitate thorough multidisciplinary pre-operative planning, rigorous patient counselling, and robust post-operative psychosocial support.

Penile cancer is rare in high-income countries (incidence approximately 1 per 100,000 males per year in the United States and Europe), but accounts for up to 10% of male malignancies in parts of South and Central America, sub-Saharan Africa, and Southeast Asia, where circumcision rates are lower and HPV exposure is higher. More than 95% of penile cancers are squamous cell carcinoma (SCC), arising from the epithelium of the glans, foreskin, or coronal sulcus. Other histological subtypes — melanoma, basal cell carcinoma, sarcoma — are rare.

Total penectomy is performed under spinal or general anaesthesia. The entire penile shaft, glans, and corpora cavernosa are excised to the level of the pubic symphysis. The urethra is redirected to a permanent perineal opening (perineal urethrostomy), which allows urination in a seated position. Simultaneously or at a separate operation, inguinal lymph node dissection may be performed to assess or treat regional nodal disease.

The decision to perform total penectomy versus organ-preserving surgery reflects a balance between oncological curability — achieving negative surgical margins — and preservation of urinary and sexual function. Advances in penile-preserving techniques have shifted surgical practice, but total penectomy remains the oncologically mandatory approach for bulky or proximal tumours.

Total penectomy is indicated primarily for penile squamous cell carcinoma in specific clinical scenarios:

Primary penile SCC — stage and location-based indications:

• T3 and T4 disease: Tumours invading the urethra (T3) or adjacent structures including the prostate, scrotum, pubic bone, or perineal soft tissues (T4) typically require total or near-total penectomy to achieve adequate oncological margins. The EAU (European Association of Urology) guidelines recommend a minimum 2 mm clear surgical margin for penile cancer, a standard that is frequently unattainable with partial penectomy when tumour bulk or proximal location limits the residual penile length to less than 1–2 cm (insufficient for directed voiding).
• Tumours of the penile base or proximal shaft: Even for T2 tumours (corpus cavernosum invasion), proximal or corporeal body-based lesions may not leave a functional residual stump after partial excision.
• Failure of penile-preserving treatment: Local recurrence after glansectomy, wide local excision, laser ablation, or radiotherapy — particularly when recurrence involves deep or proximal structures — often necessitates total penectomy as salvage therapy.
• Recurrent or multifocal disease: Multiple synchronous tumours that collectively involve most of the penile surface in patients for whom laser or topical therapy is not feasible.

Non-SCC indications (rare):

• Penile melanoma extending to shaft skin or corpora
• Locally advanced penile Paget's disease unresponsive to conservative measures
• Rare cases of penile sarcoma
• Severe traumatic degloving or penile necrosis not amenable to reconstruction

Rigorous pre-operative staging determines tumour extent, nodal involvement, and distant metastatic disease — information that is critical for surgical planning and prognosis.

Pathological diagnosis: All penile lesions undergoing planned surgery require histopathological confirmation. An incisional biopsy or punch biopsy of the primary lesion and of any suspicious inguinal node is standard. Pathology reports should include histological subtype, differentiation grade (Broders grade), depth of invasion, lymphovascular invasion, and perineural invasion — all prognostically important.

Staging work-up:

• Primary tumour: MRI of the penis with artificial erection (intracavernosal prostaglandin E1) provides the most accurate local staging, assessing corpus cavernosum invasion, urethral involvement, and scrotal extension.
• Regional nodes: Clinical assessment (palpation) is supplemented by ultrasound-guided fine-needle aspiration cytology (FNAC) of palpable nodes. PET-CT is increasingly used for regional and distant staging in T2+ or clinically node-positive disease.
• Distant disease: CT chest-abdomen-pelvis is standard. Bone scan if alkaline phosphatase elevation or bone pain is present.

Multidisciplinary team (MDT) planning: Penile cancer management should be discussed at a specialist MDT including urology, oncology, plastic and reconstructive surgery, radiology, pathology, clinical psychology, and specialist nursing. Total penectomy with immediate or delayed penile reconstruction using a radial forearm free phalloplasty or anterolateral thigh flap may be offered to select patients and should be planned pre-operatively.

Psychological and sexual health assessment: Pre-operative assessment by a psychologist or sex therapist is essential. Patients must be counselled about permanent loss of sexual function (penetrative intercourse), permanent alteration of voiding (sitting urination via perineal stoma), and the potential psychological impact on body image, relationships, and mental health.

Total penectomy is performed under spinal or general anaesthesia with the patient in the lithotomy position. Preoperative bowel preparation is not usually required, but prophylactic antibiotics are administered at induction.

Standard total penectomy with perineal urethrostomy:

A circumferential incision is made at the base of the penis, incorporating a margin of scrotal and/or perineal skin as oncologically required. The skin and subcutaneous tissue are divided down to Buck's fascia, which envelops the corpus cavernosum. Both corpora are identified, mobilised, and divided at their attachment to the pubic rami (the crura). The corpora are ligated proximally with heavy absorbable sutures and divided sharply. The urethra is identified, dissected free, and transected with an appropriate length for tension-free perineal anastomosis.

Perineal urethrostomy: A separate perineal incision is made between the ischial tuberosities, and the urethra is tunnelled subcutaneously to this perineal opening. The urethral mucosa is spatulated and sutured to the perineal skin to create a permanent, wide-calibre urinary meatus. A urethral catheter (usually 16–18 Fr) is left in situ for 10–14 days to allow mucosal healing. Voiding in the seated position through this perineal stoma is the permanent mode of urination following total penectomy.

Inguinal lymph node dissection: Staging inguinal lymphadenectomy or therapeutic bilateral inguinal node dissection (including sentinel node biopsy in clinically node-negative patients with T2+ disease) is performed at the same or a staged sitting depending on the clinical scenario. Prophylactic inguinal dissection for pN0 disease significantly improves 5-year cancer-specific survival (approximately 90% vs 40%) in patients later found to have micrometastatic nodal disease.

Penile reconstruction: In carefully selected patients, immediate or delayed penile reconstruction using microvascular free flap phalloplasty (radial forearm free flap — RFFF; anterolateral thigh flap — ALT) can be offered as part of a comprehensive rehabilitation plan. Reconstruction re-establishes a penile-shaped structure and, with the use of penile implants, may restore penetrative capacity in some patients. This is a specialist procedure performed at high-volume reconstructive urology centres.

Total penectomy offers the highest probability of achieving negative surgical margins and local disease control in appropriately selected patients with locally advanced penile cancer.

Local recurrence rates: When performed with adequate surgical margins (minimum 2 mm), local recurrence rates after total penectomy are less than 5% in most series — significantly lower than the 10–25% local recurrence rates reported after penile-preserving surgery for equivalent tumour stages. Negative margin achievement is documented in more than 95% of total penectomy specimens.

Cancer-specific survival: Penile SCC confined to the primary tumour (node-negative disease) has a 5-year cancer-specific survival exceeding 90% after radical surgery. The primary determinant of survival in penile cancer is the presence and extent of lymph node metastasis: pN0 patients have approximately 90–95% 5-year survival; pN1 patients (1–2 ipsilateral nodes) approximately 80%; pN2 patients (multiple or bilateral nodes) approximately 50%; pN3 (extranodal extension or pelvic nodes) approximately 20–30%.

Urinary function: The perineal urethrostomy creates a reliable, well-calibrated urinary meatus. When fashioned correctly with adequate spatulation and tension-free anastomosis, stenosis rates are 5–10% (lower than after partial penectomy end-urethrostomy). Urinary continence is preserved as the sphincter mechanism is uninvolved in total penectomy.

Psychological adaptation: Long-term psychological outcome data are limited but indicate that most patients achieve significant adaptation over 12–24 months, particularly with structured psychosexual rehabilitation. Body image concerns, grief reactions, and relationship difficulties are common but treatable with appropriate psychological support.

Total penectomy is a major oncological operation with significant immediate, medium-term, and long-term consequences.

Surgical complications:

• Wound infection and dehiscence: Perineal and groin wounds are at higher risk of infection due to proximity to the perineum and inguinal skin flora. Wound infection occurs in 10–20% of cases, particularly after inguinal node dissection. Meticulous wound care, prophylactic antibiotics, and negative-pressure wound therapy reduce this risk.
• Perineal urethrostomy stenosis: Meatal stenosis may impair urinary flow and require periodic urethral dilatation or surgical revision in 5–10% of patients.
• Haematoma and seroma: Common in the scrotal/perineal wound and inguinal dissection sites (seroma in up to 30–40% after inguinal lymphadenectomy). Most resolve with aspiration or conservative management.
• Lymphoedema: Lower limb lymphoedema following bilateral inguinal or pelvic lymph node dissection is the most debilitating long-term surgical complication, affecting 20–50% of patients undergoing full inguinal node dissection. Sentinel node biopsy techniques reduce lymphoedema risk to approximately 5–8%.
• Urinary tract infection: Increased risk with catheter in situ and the proximity of the perineal meatus to the anorectal region. Prophylaxis and careful catheter care minimise risk.

Functional and psychological consequences:

• Permanent loss of the ability to engage in penetrative sexual intercourse (unless penile reconstruction is performed)
• Permanent alteration of voiding posture (seated urination via perineal urethrostomy)
• Body image disturbance, depression, grief, and potential relationship and intimacy difficulties
• Sexual desire and the capacity for orgasm may be preserved in some patients, particularly those who undergo reconstruction

Pre-operative psychological assessment and robust post-operative psychosocial support — including individual therapy, psychosexual counselling, and peer support groups — are components of oncological best practice.

Post-operative recovery from total penectomy has both immediate surgical and long-term oncological dimensions.

Immediate post-operative period (Days 1–14): Patients are typically hospitalised for 5–7 days. The perineal urethral catheter remains in situ for 10–14 days. Wound care includes regular perineal hygiene, dressing changes, and assessment for infection. Analgesia is managed with multimodal regimes; non-opioid analgesics are emphasised to support early mobilisation. Venous thromboembolism (VTE) prophylaxis with LMWH is essential given the pelvic/perineal surgery in a typically older oncological population. Urinary catheter is removed at 10–14 days with voiding trial; any difficulty triggers urological review.

Short-term recovery (Weeks 2–6): Most patients are mobile and able to perform basic self-care by week 2. Perineal wound healing may take 3–6 weeks; inguinal wounds longer if lymphoedema or infection occurs. Lymphoedema management — compression garments, lymphatic drainage, physiotherapy — is initiated by a specialist lymphoedema nurse as early as clinically appropriate.

Oncological surveillance: Follow-up is life-long. EAU guidelines recommend:

• Years 1–2: Clinical examination and imaging (CT or PET-CT) every 3–6 months to detect regional or distant recurrence at an early and potentially treatable stage.
• Years 3–5: 6-monthly review with clinical assessment and targeted imaging as clinically indicated.
• Beyond 5 years: Annual review. Late recurrence (beyond 5 years) is uncommon but recognised.

Psychosocial rehabilitation: A structured psychosexual rehabilitation programme should be initiated in the early post-operative period. This includes assessment by a clinical psychologist, psychosexual therapy (individual and couple-based), peer support groups (penile cancer patient advocacy organisations), and, where applicable, referral for surgical reconstruction planning.

Total penectomy for penile cancer is generally covered by public health insurance systems in countries where it is available, as it is a non-elective oncological procedure. For patients accessing care internationally or in private health systems, costs are substantial and reflect the complexity of the surgery, required staging investigations, and potential for inguinal lymph node dissection.

Key cost drivers:

• Staging investigations: MRI of the penis, PET-CT, and FNAC of inguinal nodes add USD 2,000–6,000 to pre-operative work-up costs in private markets.
• Inguinal lymph node dissection: Bilateral inguinal dissection adds 60–90 minutes of operative time, specialised surgical expertise, and significantly increases post-operative nursing requirements. Sentinel node biopsy requires nuclear medicine and pathology expertise but is less costly than full dissection.
• Hospital length of stay: 5–10 days in-patient stay contributes substantially to total cost in fee-for-service markets.
• Penile reconstruction (if undertaken): Free flap phalloplasty is among the most technically demanding reconstructive procedures in urology; total reconstruction costs (surgeon, anaesthetist, facility, implants) may add USD 20,000–50,000 to the total treatment episode.

Approximate total penectomy cost (surgery + hospitalisation, excluding reconstruction):

• United States: USD 20,000–60,000
• United Kingdom (private): GBP 12,000–25,000
• India: USD 4,000–10,000
• Thailand: USD 6,000–15,000
• Turkey: USD 5,000–12,000

Patients considering travel abroad for treatment of penile cancer should ensure the receiving centre has demonstrable oncological urology subspecialty expertise, access to multidisciplinary oncology team support, and robust pathology services capable of rapid intra-operative frozen section analysis.

Organ-preserving approaches have become the preferred treatment for penile cancer whenever oncologically safe. They are appropriate for early-stage, distal lesions (primarily involving the glans and foreskin) and are associated with equivalent cancer-specific survival in appropriately selected patients compared with radical surgery, along with superior quality of life.

1. Partial Penectomy: Removal of the distal penis with a margin adequate to achieve clear resection margins, leaving a functional residual penile stump of at least 3–4 cm for directed urination. Appropriate for T1–T2 glans or distal shaft tumours where the residual stump will maintain voiding capacity. Local recurrence rate is 5–10%; second surgery or completion total penectomy may be required. Partial penectomy with primary shaft reconstruction using flap closure can maximise residual length.

2. Glansectomy (Total or Partial): Selective removal of all or part of the glans penis, typically using electrocautery, cold-steel, or laser dissection. The corpora are preserved and covered with a split-thickness skin graft or glans reconstruction. Appropriate for Tis (carcinoma in situ), T1a (lamina propria invasion without vascular or perineural invasion), and selected T1b lesions of the glans. Local recurrence is higher than after penectomy (~15–20%) but is often salvageable with further surgery. Superior cosmetic and functional outcomes compared to amputation techniques.

3. Mohs Micrographic Surgery: Staged tissue excision with real-time frozen section margin analysis, originally developed for skin cancers, has been adapted for selected penile cancer cases. Best suited for small (<2 cm), well-differentiated, superficial (Tis, T1a) lesions on the glans or prepuce where maximal tissue preservation is desired. Not applicable to invasive (T2+) or high-grade lesions. Requires a dermatological surgeon with penile Mohs experience.

4. Laser Ablation (CO2 or Nd:YAG Laser): Laser destruction of superficial penile lesions (Tis, grade 1 T1a) under local or general anaesthesia. Provides excellent cosmetic results but does not yield a specimen for margin assessment. Requires close surveillance for recurrence. Not appropriate for invasive disease.

5. Radiotherapy (Brachytherapy or External Beam): Penile-preserving radiotherapy — particularly interstitial brachytherapy (Ir-192) — has a long European evidence base for T1–T2 glans tumours less than 4 cm in diameter. 5-year local control rates of 70–80% with penile preservation in 60–80% of patients. Complications include urethral stenosis (10–15%) and soft tissue necrosis (10%). An option primarily in specialist European centres.

6. Systemic Therapies: For unresectable or metastatic penile cancer, neoadjuvant or palliative chemotherapy regimens — most commonly paclitaxel + ifosfamide + cisplatin (TIP) or bleomycin + methotrexate + cisplatin (BMP) — may achieve tumour downstaging that allows subsequent surgical resection. Immunotherapy (anti-PD-1 agents) is under active investigation in clinical trials for advanced penile SCC.